Olpasiran Slashes Lp(a) Levels in Phase 2 Cardiovascular Trial
Amgen's siRNA therapy olpasiran targets lipoprotein(a), a stubborn cardiovascular risk factor with no approved treatments.
Summary
Lipoprotein(a), or Lp(a), is a genetically determined cholesterol particle that significantly raises the risk of heart attack and stroke — yet no approved therapy can effectively lower it. This completed Phase 2 trial, sponsored by Amgen, tested olpasiran, a small interfering RNA (siRNA) drug delivered by subcutaneous injection, to see how much it could reduce Lp(a) levels compared to placebo. The OCEAN(a)-DOSE study enrolled patients with cardiovascular disease and measured percent change in Lp(a) from baseline across different olpasiran doses. Results from the completed trial established the dose-response relationship needed to advance olpasiran into larger Phase 3 outcomes trials. This represents a meaningful step forward in addressing one of cardiology's most persistent unmet needs.
Detailed Summary
Lipoprotein(a) is an independent, genetically driven cardiovascular risk factor carried by roughly 20% of the global population at dangerous levels. Unlike LDL cholesterol, Lp(a) cannot be meaningfully reduced by diet, exercise, or statins. Elevated Lp(a) is associated with increased risk of heart attack, stroke, aortic stenosis, and premature coronary artery disease — yet until recently, no therapy specifically targeted it. This has represented one of cardiology's most significant unmet needs for decades.
The OCEAN(a)-DOSE trial was a Phase 2 randomized, placebo-controlled study sponsored by Amgen, registered in July 2020. It evaluated olpasiran, a small interfering RNA (siRNA) that silences the gene responsible for Lp(a) production in the liver. Participants with established cardiovascular disease received olpasiran via subcutaneous injection at various doses compared with placebo, with the primary endpoint being percent change from baseline in Lp(a) concentration.
The trial was completed, and published data from the full study (NEJM, 2022) demonstrated that olpasiran reduced Lp(a) levels by up to 95% from baseline at the highest doses tested — a magnitude of reduction never before achieved with any therapeutic agent. All active doses significantly outperformed placebo. The dose-response data generated in this Phase 2 study were critical for selecting the doses now being evaluated in the Phase 3 OCEAN(a)-Outcomes trial.
The clinical implications are profound. If Lp(a) lowering translates to reduced cardiovascular events — as the ongoing outcomes trial aims to confirm — olpasiran could become the first approved therapy to address this genetically fixed risk factor. Patients with high Lp(a) who have exhausted conventional lipid-lowering options may finally have a targeted option.
Caveats remain important. This was a dose-finding study, not powered to detect differences in clinical outcomes such as heart attacks or mortality. The summary here is based on the abstract and registry data only. Whether Lp(a) reduction with olpasiran translates to event reduction awaits Phase 3 results.
Key Findings
- Olpasiran reduced Lp(a) by up to ~95% from baseline at higher doses in Phase 2 testing.
- All active olpasiran doses significantly outperformed placebo in Lp(a) lowering.
- Drug was delivered via subcutaneous injection, supporting outpatient or self-administration use.
- Dose-response data from this trial informed Phase 3 OCEAN(a)-Outcomes trial dose selection.
- No approved therapy currently exists that meaningfully lowers genetically elevated Lp(a).
Methodology
Randomized, placebo-controlled Phase 2 dose-finding study in patients with established cardiovascular disease. Olpasiran was administered subcutaneously at multiple dose levels versus placebo. Primary endpoint was percent change from baseline in Lp(a) concentration.
Study Limitations
This summary is based on the clinical trial abstract and registry data only, as the full manuscript was not available for review. The Phase 2 design was not powered to detect differences in cardiovascular events or mortality. Long-term safety, durability of effect, and outcomes benefit remain to be established in the Phase 3 trial.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.